Liquid Biopsy Market: Market Size, Trends and Growth Analysis

Liquid Biopsy Market: Market Size, Trends and Growth Analysis

Liquid Biopsy Market Trends and Forecast

The future of the global liquid biopsy market looks promising with opportunities in reference laboratories, hospitals and physician laboratories, and academic and research centers. The global liquid biopsy market is expected to reach an estimated $10.4 billion by 2027 with a CAGR of 17.9% from 2022 to 2027. The major drivers for this market are the increasing prevalence of cancer, preference for non-invasive procedures, and increasing need of early detection of high precision diseases in real time.

Emerging Trends in Liquid Biopsy Market

Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.

A total of 163 figures / charts and 129 tables are provided in this 264-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global liquid biopsy market report, please download the report brochure.

Liquid Biopsy Market by Segment

In this market, therapy selection is the largest clinical application market, and circulating tumor DNA is the largest circulating biomarker segment. Growth in various segments of the liquid biopsy market are shown in the figure below.

The study includes trends and forecast for the global liquid biopsy market by product, circulating biomarker, application, clinical application, end use, and region as follows:

Liquid Biopsy Market by Product [Value ($M) from 2016 to 2027]:

• Assays Kits
• Instruments
• Services

Liquid Biopsy Market by Circulating Biomarker [Value ($M) from 2016 to 2027]:

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (CtDNA)
• Cell-Free DNA (cfDNA)
• Extracellular Vesicles (EVs)
• Other Biomarkers

Liquid Biopsy Market by Application [Value ($M) from 2016 to 2027]:

• Oncology
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Other Cancers
• Non-Cancer

Liquid Biopsy Market by Clinical Application [Value ($M) from 2016 to 2027]:

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

Liquid Biopsy Market by End Use [Value ($M) from 2016 to 2027]:

• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic and Research Centers
• Other End Uses

Liquid Biopsy Market by Region [Value ($M) from 2016 to 2027]:

• North America
• US
• Canada
• Mexico
• Europe
• United Kingdom
• France
• Germany
• Italy
• Spain
• APAC
• China
• Japan
• India
• ROW
• Brazil

List of Liquid Biopsy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, liquid biopsy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liquid biopsy companies profiled in this report include-

• Guardant
• Bio-Rad Laboratories
• Qiagen
• MDxHealth
• Myriad Genetics
• Biocept
• Roche
• Illumina
• Thermofisher

Liquid Biopsy Market Insights

• Lucintel forecasts circulating tumor DNA will remain the largest segment and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.
• Therapy selection will remain the largest clinical application over the forecast period due to its offerings of various benefits, such as non-invasiveness, access to tumor heterogeneity, real-time treatment monitoring, and recurrence detection in advance of significant tumor formation or metastasis.
• APAC will remain the fastest growing region over the forecast period due to rising non-invasive treatment, a rising incidence of cancer, and improving healthcare infrastructure.

Features of the Global Liquid Biopsy Market

• Market Size Estimates: Global liquid biopsy market size estimation in terms of value ($B) shipment.
• Trend and Forecast Analysis: Market trends (2016-2021) and forecast (2022-2027) by various segments.
• Segmentation Analysis: Global liquid biopsy market size by product, circulating biomarker, application, clinical application, end use, and region in terms of value.
• Regional Analysis: Global liquid biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different by product, circulating biomarker, application, clinical application, end use, and region for the global liquid biopsy market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global liquid biopsy market.
• Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is theliquid biopsy marketsize?

Answer:The global liquid biopsy market is expected to reach an estimated $10.4 billion by 2026.

Q2. What is the growth forecast for theliquid biopsy market?

Answer:The global liquid biopsy market is expected to grow at a CAGR of ~17% from 2020 to 2026.

Q3. What are the major drivers influencing the growth of theliquid biopsy market?

Answer: The major drivers for this market are increasing prevalence of cancer, preference for non-invasive procedures, and increasing need for early detection of high precision diseases in real time.

Q4. What are the major clinical applications of theliquid biopsy market?

Answer:Early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring are the major clinical application segments of liquid biopsy.

Q5. What are the emerging trends in theliquid biopsy market?

Answer:Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.

Q6. Who are the keyliquid biopsy companies?

Answer:Some of the key liquid biopsy companies are as follows:

• Guardant
• Bio-Rad Laboratories
• Qiagen
• MDxHealth
• Myriid Genetics
• Biocept
• Roche
• Illumina
• Thermofisher

Q7.Which will be the largestcirculating biomarker segment of theliquid biopsy marketin the future?

Answer: Lucintel forecasts that circulating tumor DNA (ctDNA) will remain the largest segment, and it is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in the early stage.

Q8: Inliquid biopsy market, which region is expected to be the largest in the next five years?

Answer:Asia Pacific is expected to be the largest region over the next five years.

Q9. Do we receive customization in this report?

Answer:Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions

Q.1 What are some of the most promising growth opportunities for the global liquid biopsy market by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end uses), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2 Which segments will grow at a faster pace and why?

Q.3 Which region will grow at a faster pace and why?

Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global liquid biopsy market?

Q.5 What are the business risks and threats to the global liquid biopsy market?

Q.6 What are the emerging trends in this liquid biopsy market and the reasons behind them?

Q.7 What are some changing demands of customers in the liquid biopsy market?

Q.8 What are the new developments in the liquid biopsy market? Which companies are leading these developments?

Q.9 Who are the major players in the liquid biopsy market? What strategic initiatives are being implemented by key players for business growth?

Q.10 What are some of the competitive products and processes in the liquid biopsy market, and how big of a threat do they pose for loss of market share via material or product substitution?

Q.11 What M&A activities did take place in the last five years in the global liquid biopsy market?

Please note: it takes 2 weeks’ time for reports to be delivered after receiving the order confirmation.